Skip to main content
SpringerLink
Log in

Pharmacologic treatment of schizoaffective disorder

  • Reviews
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

In contrast to the considerable systematic study of the pharmacologic treatment of schizophrenia and mood disorders, the pharmacologic treatment of schizoaffective disorder has been relatively ignored. The authors reviewed the available literature regarding the pharmacologic treatment of schizoaffective disorder. The total number of controlled studies of the acute and prophylactic treatment of schizoaffective disorder was small and few used modern criteria to define the disorder. In studies of schizoaffective disorder, bipolar type (manic), lithium and antipsychotics produced comparable albeit incomplete responses, except in highly agitated patients when antipsychotics exerted superior efficacy. The combination of lithium and antipsychotics appeared to be superior to antipsychotics alone for schizoaffective, bipolar type patients. In the only controlled study of schizoaffective disorder, depressed type, the presumed superiority of combined antidepressant and antipsychotic treatment to antipsychotic alone was not found. Although combined antipsychotic and thymoleptic treatment represents common prophylactic management of schizoaffective disorder in clinical practice, the efficacy of this strategy has not been studied in controlled trials. Advances in the nosology of schizoaffective disorder, emerging epidemiologic data demonstrating large numbers of patients with this disorder in clinical populations, and preliminary evidence that clozapine may have combined antipsychotic and thymoleptic properties as well as efficacy in both the psychotic and affective components of schizoaffective disorder, suggest that renewed interest in the diagnosis and treatment of this disorder may lead to improved delivery of care for this understudied but seriously ill group of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abrams R, Taylor MA (1976) Mania and schizoaffective disorder, manic type: a comparison. Am J Psychiatry 133:1445–1447

    Google Scholar 

  • Abrams R, Taylor MA (1981) Importance of schizophrenic symptoms in the diagnosis of mania. Am J Psychiatry 138:658–661

    Google Scholar 

  • Alexander PE, Van Kammen DP, Bunney WE (1979) Antipsychotic effects of lithium in schizophrenia. Am J Psychiatry 136:282–287

    Google Scholar 

  • American Psychiatric Association (1952) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington DC

    Google Scholar 

  • American Psychiatric Association (1968) Diagnostic and statistical manual of mental disorders, 2nd edn. American Psychiatric Association, Washington DC

    Google Scholar 

  • American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, Revised. American Psychiatric Press, Washington DC

    Google Scholar 

  • Angst J, Dittrich A, Grof P (1969) The course of endogenous affective psychosis and its modification by prophylactic treatment. Int Pharmacopsychiatry 2:1–11

    Google Scholar 

  • Angst J, Weis P, Grof P Baastrup PC, Shou M (1970) Lithium prophylaxis in recurrent affective disorders. Br J Psychiatry 125:604–614

    Google Scholar 

  • Aprison MH, Takahashi R, Tachiki K (1978) Hypersensitive serotonergic receptors involved in clinical depression — a theory. In: Haber B, Aprison MH (eds) Neuropharmacology and behavior. Plenum, New York, pp 23–48

    Google Scholar 

  • Arora RC, Meltzer HY (1989a) Increased serotonin2 (5-HT2) receptor binding as measured by3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patients. Life Sci 44:725–734

    Google Scholar 

  • Arora RC, Meltzer HY (1989b) Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. Am J Psychiatry 146:730–736

    Google Scholar 

  • Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM (1992) Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 160 [Suppl 17]:12–16

    Google Scholar 

  • Banov MD, Zarate CA, Scialabba BA, Tohen M, Wines J (1993) Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. American Psychiatric Association Annual Meeting Abstract 163, San Francisco

  • Biederman J, Lerner Y, Belmaker RH (1979) Combination of lithium carbonate and haloperidol in schizoaffective disorder. Arch Gen Psychiatry 36:327–333

    Google Scholar 

  • Bigelow LB, Weinberger DR, Wyatt RJ (1981) Synergism of combined lithium-neuroleptic therapy: a double-blind, placebo-controlled case study. Am J Psychiatry 138:81–83

    Google Scholar 

  • Bigeon A, Weizman A, Karp L, Ram A, Tiano S, Wolff M (1987) Serotonin 5-HT2 receptor binding on blood platelets — a peripheral marker for depression? Life Sci 41:2485–2492

    Google Scholar 

  • Blackshear MA, Sanders-Bush E (1982) Serotonin receptor sensitivity after acute and chronic treatment with mianserin. J Pharmacol Exp Ther 221:303–308

    Google Scholar 

  • Braden W, Fink EB, Qualls CB, Ho CK, Samuels WO (1982) Lithium and chlorpromazine in psychotic inpatients. Psychiatry Res 7:69–81

    Google Scholar 

  • Brockington IF, Leff JP (1979) Schizoaffective psychosis: definitions and incidence. Psychol Med 9:91–99

    Google Scholar 

  • Brockington IF, Kendall RE, Kellett JM, Curry SH, Wainwright S (1978) Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients. Br J Psychiatry 133:162–168

    Google Scholar 

  • Brockington IF, Wainwright S, Kendall RE (1980) Manic patients with schizophrenic or paranoid symptoms. Psychol Med 10:73–83

    Google Scholar 

  • Brockington IF, Roper A, Copas J, Buckley M, Andrade CE, Wigg P, Farmer A, Kaufman C, Hawley R (1991) Schizophrenia, bipolar disorder and depression. A discriminant analysis, using „lifetime“ psychopathology ratings. Br J Psychiatry 159:485–494

    Google Scholar 

  • Calabrese JR, Meltzer HY, Markovitz PJ (1991) Clozapine prophylaxis in rapid cycling bipolar disorder. J Clin Psychopharmacol 11:396–397

    Google Scholar 

  • Carman JS, Bigelow LB, Wyatt RJ (1981) Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 42:124–128

    Google Scholar 

  • Casey DE (1992) What makes a neuroleptic atypical? In: Meltzer HY (ed) Novel antipsychotic drugs. Raven, New York, pp 241–251

    Google Scholar 

  • Chalmers TL (1992) The potential impact of meta-analysis on medical care. In: Fava M, Rosenbaum JF (eds) Research designs and methods in psychiatry. Elsevier, Amsterdam, pp 85–89

    Google Scholar 

  • Cheetham SC, Crompton MR, Katona CLE, Horton RW (1988) Brain 5-HT2 receptor binding sites in depressed suicide victims. Brain Res 443:272–280

    Google Scholar 

  • Cole JO, Banov MD, Green A, Tohen M, Patel J (1993) Clozapine in the treatment of refractory acute bipolar mania. American Psychiatric Association Annual Meeting Abstract 455, San Francisco

  • Cowen PJ, Charig EM, Fraser S, Elliott JM (1987) Platelet 5-HT receptor binding during depressive illness and tricyclic antidepressant treatment. J Affective Disord 13:45–50

    Google Scholar 

  • Croughan JL, Welner A, Robins E (1974) The group of schizoaffective and related psychoses — critique, record, follow-up, and family studies. Arch Gen Psychiatry 31:632–637

    Google Scholar 

  • Crow TJ, Cross AJ, Cooper SJ, Deakin JFW, Ferrier IN, Johnson JA, Joseph MH, Own F, Poulter M, Lofthouse R, Corsellis JAN, Chambers DR, Blessed G, Perry EK, Perry RH, Tomlinson BE (1984) Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 23:1561–1569

    Google Scholar 

  • Engleman EA, Murphy JM, Zhou FE, Hingtgen JN (1992) Response suppression induced with selective 5-HT agonists can be differentially blocked with LY53857 in an animal model of depression. Neurochem Res 17:483–488

    Google Scholar 

  • Feighner JP, Robins E, Guze SB, Woodruff RD, Winokur G, Munoz R (1972) Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 26:57–63

    Google Scholar 

  • Frankenburg FR (1993) Clozapine and bipolar disorder. J Clin Psychopharmacol 13:289–290

    Google Scholar 

  • Gandolfi O, Barbaccia ML, Costa E (1984) Different effects of serotonin antagonists on3H-kitanserin recognition sites. Life Sci 36:713–721

    Google Scholar 

  • Goodnick PJ, Meltzer HY (1984) Treatment of schizoaffective disorders. Schizophr Bull 10:30–48

    Google Scholar 

  • Growe GA, Crayton JW, Klass DB, Evans H, Strizich M (1979) Lithium in chronic schizophrenia. Am J Psychiatry 136:454–455

    Google Scholar 

  • Himmelhoch JA, Fuchs CZ, May SJ (1981) When schizoaffective diagnosis has meaning. J Nerv Ment Dis 169:277–282

    Google Scholar 

  • Hingtgen JN, Hendrie HC, Aprison MH (1983) Postsynaptic serotonergic blockade following chronic antidepressive treatment with trazodone in an animal model of depression. Pharmacol Biochem Behav 20:425–428

    Google Scholar 

  • Hingtgen JN, Fuller RW, Mason NR (1985) Blockade of a 5-hydroxytryptophan-induced animal model of depression with a potent and selective 5-HT2 receptor antagonist (LY53857). Biol Psychiatry 20:592–597

    Google Scholar 

  • Johnson G, Gershon S, Hekiman LJ (1968) Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: an interim report. Compr Psychiatry 9:563–573

    Google Scholar 

  • Johnson G, Gershon S, Burdock EI, Floyd A, Hekiman L (1971) Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. Br J Psychiatry 119:267–276

    Google Scholar 

  • Kasanin J (1933) The acute schizoaffective psychoses. Am J Psychiatry 13:97–126

    Google Scholar 

  • Keck PE, McElroy SL, Nemeroff CB (1992) Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 4:395–405

    Google Scholar 

  • Keck PE, McElroy SL, Strakowski SM, Tugrul KC, Hawkins JM, Huber TJ, Newman RM (1993) Comorbidity in first-compared with multiple-episode mania. American Academy of Clinical Psychiatrists Annual Meeting Abstracts, Chicago

  • Kendler KS, Gruenberg AM, Tsuang MT (1986) A DSM-III family study of nonschizophrenic psychotic disorders. Am J Psychiatry 143:1098–1106

    Google Scholar 

  • Lapenseé MA (1992) A review of schizoaffective disorder: II. Somatic treatment. Can J Psychiatry 37:347–349

    Google Scholar 

  • Lee CK, Kwak YS, Rhee H, Kim YS, Han JH, Choi JO, Lee YH (1987) The nationwide epidemiological study of mental disorders in Korea. J Korean Med Sci 2:19–34

    Google Scholar 

  • Levenson DF, Levitt MEM (1987) Schizoaffective mania reconsidered. Am J Psychiatry 144:415–425

    Google Scholar 

  • Levitt JJ, Tsuang MT (1988) The heterogeneity of schizoaffective disorder: implications for treatment. Am J Psychiatry 145:926–936

    Google Scholar 

  • Lindström LH (1989) A retrospective study of the long-term efficacy and safety of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period. Psychopharmacology 99[Suppl]:84–86

    Google Scholar 

  • Maes M, De Ruyter M, Claes R, Bosma G, Suy E (1989) The cortisol response to 5-hydroxytryptophan, orally, in depressive inpatients. J Affective Disord 13:23–30

    Google Scholar 

  • Maier W, Lichterman D, Minges J, Heun R, Hallmayer J, Benkert O (1992) Schizoaffective disorder and affective disorders with mood-incongruent psychotic features: keep separate or combine? Evidence from a family study. Am J Psychiatry 149:1666–1673

    Google Scholar 

  • Maj M (1984) Evolution of the American concept of schizoaffective psychosis. Neuropsychobiology 11:7–13

    Google Scholar 

  • Malhotra A, Litman RE, Su TP, Smyser CH, Pickar D (1993) Clozapine response in schizoaffective disorder. American Psychiatric Association Annual Meeting Abstract 53, San Francisco

  • Mann JJ, Stanley M, McBride PA, McEwen BS (1986) Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 43:954–959

    Google Scholar 

  • Marneros A, Rohde A, Diester A (1989) Unipolar and bipolar schizoaffective disorders: a comparative study. Eur Arch Psychiatr Neurol Sci 239:164–170

    Google Scholar 

  • Marneros A, Diester A, Rohde A (1991) Stability of diagnoses in affective, schizoaffective and schizophrenic disorders. Eur Arch Psychiatr Clin Neurosci 241:187–192

    Google Scholar 

  • Mattes JA, Nayak D (1984) Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizoaffectives. Biol Psychiatry 19:445–449

    Google Scholar 

  • McElroy SL, Keck PE (1993) Treatment guidelines for valproate in bipolar and schizoaffective disorders. Can J Psychiatry 38[Suppl 2]:62–66

    Google Scholar 

  • McElroy SL, Dessain EC, Pope HG, Cole JO, Keck PE, Frankenburg FR, Aizley HG, O'Brien S (1991) Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 52:411–414

    Google Scholar 

  • McKeith IG, Marshall EF, Ferrier IN, Armstrong MM, Kennedy WN, Perry RH, Perry EK, Eccleston D (1987) 5-HT receptor binding in post-mortem brain from patients with affective disorder. J Affective Disord 13:67–74

    Google Scholar 

  • Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27

    Google Scholar 

  • Meltzer HY (1992) The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 1–13

    Google Scholar 

  • Meltzer HY, Umberkoman-Wiita B, Robertson A, Tricou BJ, Lowy M, Perline R (1984) Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. Arch Gen Psychiatry 41:366–374

    Google Scholar 

  • Müller-Oerlinghausen B, Ahrens B, Grof E, Grof P, Lenz G, Sihou M, Simhandl C, Thau K, Volk J, Wolf R, Wolf T (1992) The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand 86:218–272

    Google Scholar 

  • Naber D, Hippius H (1990) The European experience with use of clozapine. Hosp Commun Psychiatry 41:886–890

    Google Scholar 

  • Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanga K (1989) A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 80:250–259

    Google Scholar 

  • Owen F, Chambers DR, Cooper SJ, Crow TJ, Johnson JA, Lofthouse R, Poulter M (1986) Serotonergic mechanisms in brains of suicide victims. Brain Res 362:185–188

    Google Scholar 

  • Pandey GN, Pandey SC, Janicak PG, Marks RC, Davis JM (1990) Platelet serotonin-2 receptor binding sites in depression and suicide. Biol Psychiatry 28:215–222

    Google Scholar 

  • Parsa MA, Ramirez LF, Loula EC, Meltzer HY (1991) Effect of clozapine on psychotic depression and Parkinsonism. J Clin Psychopharmacol 11:330–331

    Google Scholar 

  • Peroutka SJ, Snyder SH (1980) Regulation of serotonin2 (5-HT2) receptors labeled with [3H] spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther 215:582–587

    Google Scholar 

  • Placidi GF, Lenzi A, Lazzerini F, Cassano GB, Akiskal HS (1986) The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 47:490–494

    Google Scholar 

  • Pope HG, Lipinski JF, Cohen BM, Axelrod DT (1980) “Schizoaffective disorder”: An invalid diagnosis? A comparison of schizoaffective disorder, schizophrenia, and affective disorder. Am J Psychiatry 137:921–927

    Google Scholar 

  • Prien RF, Point P, Caffey EM, Klett CJ (1972) A comparison of lithium carbonate and chlorpromazine in the treatment of excited schizoaffectives. Arch Gen Psychiatry 27:182–189

    Google Scholar 

  • Prien RF, Caffey EM, Klett CJ (1974) Factors associated with treatment success in lithium carbonate prophylaxis. Arch Gen Psychiatry 31:189–192

    Google Scholar 

  • Privitera MR, Lamberti JS, Maharaj K (1993) Clozapine in a bioplar depressed patient. Am J Psychiatry 150:986

    Google Scholar 

  • Reyntjens A, Gelders YG, Hoppenbrouwers M-LJA, Bussche GV (1986) Thymosthenic effects of ritanserin, a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 8:205–211

    Google Scholar 

  • Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD, Regier DA (1984) Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41:949–958

    Google Scholar 

  • Rosenthal NE, Rosenthal LN, Stallone F, Dunner DL, Fieve RR (1980) Toward the validation of RDC schizoaffective disorder. Arch Gen Psychiatry 37:804–810

    Google Scholar 

  • Shopsin B, Kim SS, Gershon S (1971) A controlled study of lithium vs. chlorpromazine in acute schizophrenics. Br J Psychiatry 119:435–440

    Google Scholar 

  • Simhandl C, Meszaros K (1992) The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review. J Psychiatr Neurosci 17:1–14

    Google Scholar 

  • Skodol AE (1987) Problems in differential diagnosis: from DSM-III to DSM-III-R in clinical practice. American Psychiatric Press, Washington DC

    Google Scholar 

  • Skodol AE, Spitzer RL (1987) An annotated bibliography of DSM-III. American Psychiatric Press, Washington DC

    Google Scholar 

  • Small JG, Kellams JJ, Milstein V, Moore J (1975) A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 132:1315–1317

    Google Scholar 

  • Spitzer RL, Endicott J, Robins E (1978) Research diagnostic criteria. Rationale and reliability. Arch Gen Psychiatry 35:773–782

    Google Scholar 

  • Stanley M, Mann JJ (1983) Increased serotonin-2 binding sties in frontal cortex of suicide victims. Lancet i:214–216

    Google Scholar 

  • Stefanowicz P (1990) Initial results of clozapine and lithium carbonate treatment of manic syndromes in the course of schizoaffective psychosis. Psychiatr Pol 24:27–30

    Google Scholar 

  • Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO (1992) Clozapine in the treatment of dysphoric mania. Biol Psychiatry 32:270–280

    Google Scholar 

  • Tsuang MT (1991) Morbidity risks of schizophrenia and affective disorders among first-degree relatives of patients with schizoaffective disorders. Br J Psychiatry 158:165–170

    Google Scholar 

  • Tsuang D, Coryell W (1993) An 8-year follow-up of patients with DSM-III-R psychotic depression, schizoaffective disorder, and schizophrenia. Am J Psychiatry 150:1182–1188

    Google Scholar 

  • Williams PV, McGlashan TH (1987) Schizoaffective psychosis I. Comparative long-term outcome. Arch Gen Psychiatry 44:130–137

    Google Scholar 

  • Williams JBW, Gibbon M, First MB, Spitzer RL, Davies M, Borus J, Howes MJ, Kane J, Pope HG, Rounsaville B, Wittchen HAU (1992) The structured clinical interview for DSM-III-R (SCID) II. Multisite test-retest reliability. Arch Gen Psychiatry 49:630–636

    Google Scholar 

  • Wilmot CA, Szczepanik AM (1989) Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res 487:288–298

    Google Scholar 

  • Winokur G (1984) Psychosis in bipolar and unipolar affective illness with special reference to schizo-affective disorder. Br J Psychiatry 145:236–242

    Google Scholar 

  • World Health Organization (1992) The ICD-10 classification of mental and behavioral disorders. World Health Organization, Geneva

    Google Scholar 

  • Yates M, Leake A, Candy JM, Fairbairn AF, McKeith IG, Ferrier IN (1990) 5HT2 receptor changes in major depression. Biol Psychiatry 27:489–496

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biological Psychiatry Program, Departments of Psychiatry, Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

    Paul E. Keck Jr., Susan L. McElroy, Stephen M. Strakowski & Scott A. West

Authors
  1. Paul E. Keck Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan L. McElroy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen M. Strakowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Scott A. West
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported in part by a grant from the Alliance for the Mentally Ill, Hamilton County, Ohio.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keck, P.E., McElroy, S.L., Strakowski, S.M. et al. Pharmacologic treatment of schizoaffective disorder. Psychopharmacology 114, 529–538 (1994). https://doi.org/10.1007/BF02244982

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02244982

Key words

Search

Navigation